Upstream Bio, Inc. (NASDAQ:UPB) Receives $33.17 Average Price Target from Analysts

by · The Cerbat Gem

Upstream Bio, Inc. (NASDAQ:UPB – Get Free Report) has been given a consensus rating of “Hold” by the seven ratings firms that are currently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the company. The average 12 month price target among brokers that have covered the stock in the last year is $33.1667.

Several research firms have recently weighed in on UPB. HC Wainwright began coverage on Upstream Bio in a report on Wednesday, June 3rd. They set a “buy” rating and a $36.00 price objective on the stock. Weiss Ratings downgraded shares of Upstream Bio from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, May 6th. JPMorgan Chase & Co. cut shares of Upstream Bio from an “overweight” rating to a “neutral” rating and reduced their price target for the company from $35.00 to $8.00 in a report on Friday, June 12th. Wall Street Zen downgraded shares of Upstream Bio from a “hold” rating to a “sell” rating in a research report on Saturday, March 28th. Finally, Mizuho dropped their price objective on shares of Upstream Bio from $51.00 to $50.00 and set an “outperform” rating on the stock in a report on Thursday, May 14th.

Check Out Our Latest Analysis on Upstream Bio

Upstream Bio Trading Down 3.6%

Shares of Upstream Bio stock opened at $7.53 on Monday. The company has a market capitalization of $409.78 million, a PE ratio of -2.59 and a beta of 1.23. Upstream Bio has a 12 month low of $5.85 and a 12 month high of $33.68. The stock’s fifty day simple moving average is $7.62 and its 200 day simple moving average is $13.88.

Upstream Bio (NASDAQ:UPB – Get Free Report) last posted its earnings results on Wednesday, May 13th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.73) by ($0.02). Upstream Bio had a negative net margin of 4,718.96% and a negative return on equity of 43.82%. The business had revenue of $1.03 million during the quarter, compared to analyst estimates of $1.03 million. Analysts predict that Upstream Bio will post -2.9 EPS for the current fiscal year.

Hedge Funds Weigh In On Upstream Bio

Institutional investors have recently modified their holdings of the business. Norges Bank acquired a new stake in shares of Upstream Bio during the fourth quarter valued at about $78,264,000. Vanguard Group Inc. grew its stake in shares of Upstream Bio by 12.5% in the third quarter. Vanguard Group Inc. now owns 2,442,551 shares of the company’s stock worth $45,944,000 after purchasing an additional 271,718 shares during the last quarter. UBS Group AG increased its holdings in Upstream Bio by 563.4% in the fourth quarter. UBS Group AG now owns 1,806,243 shares of the company’s stock valued at $49,039,000 after purchasing an additional 1,533,972 shares during the period. Janus Henderson Group PLC acquired a new stake in Upstream Bio in the fourth quarter valued at $41,423,000. Finally, State Street Corp raised its position in Upstream Bio by 18.4% during the 4th quarter. State Street Corp now owns 1,319,226 shares of the company’s stock worth $35,817,000 after purchasing an additional 204,645 shares during the last quarter.

Upstream Bio Company Profile

(Get Free Report)

Upstream Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation prophylactic vaccines and immuno-oncology therapies. Leveraging a proprietary viral vector platform, the company aims to deliver optimized antigen payloads that stimulate robust and durable immune responses against both infectious diseases and cancer targets. Upstream Bio’s approach emphasizes safety, manufacturability and potential for rapid scale-up to address emerging public health challenges.

The company’s research and development pipeline includes multiple viral vector-based candidates in early clinical and preclinical stages.

Featured Stories